With nearly 15 million people, Ontario is Canada’s most populated and arguably research-active province; it is by far the largest provincial economy as measured by total GDP. The government there is now funding COVID-19 research focusing on projects involving the...
Financing
Category
Kymera Therapeutics Secures $102m Series C to Advance Protein Degrader Pipeline
Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced the closing of a $102 million Series C financing. The round was led by Biotechnology Value Fund...
China Biotech Arrives: the IPO of I-Mab and the Push for Immuno-Oncology Domination in China
China-based I-Mab (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet needs—particularly cancers and autoimmune...
Does Kyverna Therapeutics Gilead Financing Introduce Disruptive Cell Therapy Platform to Attack Autoimmune Disease?
Engineering a new class of cell therapy for autoimmune diseases, Kyverna Therapeutics (Kyverna) announced it raised $25 million in a Series A financing from a group of investors, including prominent biotech Gilead. Proceeds will be used to advance their therapeutic...
UB’s Empire Discovery Institute Funding & Supporting Early Stage Clinical Investigators
The Empire Discovery Institute (EDI), a drug discovery and development accelerator in Upstate New York, invites University of Buffalo (UB) researchers and investigators interested in developing pharmaceuticals to apply for project funding and support. Established by...
The FDA Awards 12 Grants that Fund New Clinical Trials to Advance Development of Medical Products for Treatment of Rare Disease
The U.S. Food and Drug Administration (FDA) has awarded 12 new clinical trial research grants amounting to over $15 million over the next four years. They seek to enhance the development of medicinal products for patients with rare diseases. The grants were awarded to...
Swiss Biotechnology Company Anokion SA Achieves Major Acquisition and Funding, Providing Runway for Multiple Emerging Autoimmune Therapies
Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the acquisition of Kanyos Bio, Inc. and the completion of a $40 million Series B financing. Anokion has come a long way, according to...
Private Equity Giant Blackstone Muscles Into Clinical Trials & Drug Development
Look out Big Pharma; Big Finance is coming into drug development in a big way—enter Blackstone. An American multinational private equity giant, the New York City-based venture is the largest alternative investment house in the world. As of 2019 the company had...
Greater Provider & Payer Risk Sharing Equals Greater Outcomes: Where will Pharma Fit in?
The recent Integrated Healthcare Associations California Health Care Cost & Quality Atlas measures clinical quality, utilization and total cost of care in the State of California. A key takeaway is that capitation payment models equal improved outcomes and over...
Site Watch: Univ. Of Arkansas Audit Reveals Budget Issues-Layoffs
As reported on Arkansas Online, the budget adopted before recent mass layoffs at the University of Arkansas for Medical Sciences included revenue projections unsupported by calculations, or recent health care trends according to an internal audit report. Follow the...
Site Watch Deals! Montefiore Raises $1.22 Billion via State Municipal Bonds
Danielle Balbi reports for The Real Deal that Montefiore Health System just landed a $1.2 billion financing deal. The Dormitory Authority of the State of New York (DASNY) issued $685 million in bonds on a portfolio of the hospital system’s facilities in the Bronx,...